Conduit Pharmaceuticals (NASDAQ:CDT) Posts Earnings Results

Conduit Pharmaceuticals (NASDAQ:CDT) released its quarterly earnings data on Friday. The company reported ($20.33) EPS for the quarter, Zacks reports.

Conduit Pharmaceuticals Trading Up 15.9 %

CDT stock opened at $0.89 on Friday. Conduit Pharmaceuticals has a 1-year low of $0.73 and a 1-year high of $379.00. The business’s 50 day moving average is $1.90 and its 200-day moving average is $7.12.

Conduit Pharmaceuticals Company Profile

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.